202 research outputs found
The LCG PI project: using interfaces for physics data analysis
In the context of the LHC computing grid (LCG) project, the applications area develops and maintains that part of the physics applications software and associated infrastructure that is shared among the LHC experiments. The "physicist interface" (PI) project of the LCG application area encompasses the interfaces and tools by which physicists will directly use the software, providing implementations based on agreed standards like the analysis systems subsystem (AIDA) interfaces for data analysis. In collaboration with users from the experiments, work has started with implementing the AIDA interfaces for (binned and unbinned) histogramming, fitting and minimization as well as manipulation of tuples. These implementations have been developed by re-using existing packages either directly or by using a (thin) layer of wrappers. In addition, bindings of these interfaces to the Python interpreted language have been done using the dictionary subsystem of the LCG applications area/SEAL project. The actual status and the future planning of the project will be presented
Recommended from our members
Performance assessment model of a single waste package
PANDORA-1.1 is a system model for the mobilization and release of radionuclides from a spent nuclear fuel disposal package. Earlier processes affecting release are represented by input tables. Several groundwater contact alternatives and spent fuel constituents lead to different release-rate behaviors and controlling parameters. Rate control is provided by a product of parameters from hydrology, design, and/or geochemistry/waste form interaction parameters. The program is designed to accommodate evolving requirements such as a wider range of hydrological input values. A computerized configuration management system automates much of the change control process
Recommended from our members
Post-closure performance assessment of waste packages for the Yucca Mountain Project
This report details a system model of some core features of the performance of waste packages for the permanent disposal of spent nuclear fuel at the Yucca Mountain Site. The model is realized in the prototype computer program PANDORA-1.1. The PANDORA system model links processes leading to possible release of radionuclides from the waste package. The PANDORA submodels are being developed for processes and conditions specific to this potential repository site, notably the comparatively dry location in an arid area and well above the groundwater table, and the rock medium of porous partially welded tuff
Diversity among the coat proteins of luteoviruses associated with chickpea stunt disease in India
Chickpea stunt is an important virus disease of chickpea in the Indian subcontinent which is thought to be caused by infection with a luteovirus. Samples of diseased chickpea plants were collected from different chickpea growing regions of India and analysed with a panel of monoclonal antibodies to potato leafroll, beet western yellows and barley yellow dwarf (RPV strain) luteoviruses. The results suggested that more than one luteovirus was present in chickpea crops near ICRISAT Asia Center, Hyderabad. Aphid transmission tests resulted in the separation of two distinct isolates from these samples. One of them (isolate L) was more efficiently transmitted by Myzus persicae than the other (isolate IC). Nucleotide sequence analysis of DNA obtained by reverse transcription-polymerase chain reaction (RT/PCR) amplification revealed that the amino acid sequence of the coat protein of isolate L was 94% identical to that of beet western yellows virus, whereas the coat protein sequence of isolate IC was 82% identical to that of isolate L and 80% identical or less to those of the coat protein of other luteoviruses. Using newly designed “universal luteovirus primers”, a minor sequence variant of isolate IC, which was 96% identical to it in part of the coat protein gene, was detected in the same location during the next season. Only isolate IC could be detected in samples from other locations by either serological or nucleotide sequence analysi
Diversity among the coat proteins of luteoviruses associated with chickpea stunt disease in India
Structural Perturbations Induced by the α-Anomer of the Aflatoxin B1 Formamidopyrimidine Adduct in Duplex and Single-Strand DNA
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.
Recommended from our members
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF
M. Kaste on työryhmän ROCKET AF Steering Comm jäsen.Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intention-to-treat population. The median age was 73 years, and the mean CHADS(2) score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P= 75 years (hazard ratio 1.69, 95% CI 1.51-1.90, P Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, approximate to 7 in 10 deaths were cardiovascular, whereasPeer reviewe
Improved functionalization of oleic acid-coated iron oxide nanoparticles for biomedical applications
Superparamagnetic iron oxide nanoparticles
can providemultiple benefits for biomedical applications
in aqueous environments such asmagnetic separation or
magnetic resonance imaging. To increase the colloidal
stability and allow subsequent reactions, the introduction
of hydrophilic functional groups onto the particles’
surface is essential. During this process, the original
coating is exchanged by preferably covalently bonded
ligands such as trialkoxysilanes. The duration of the
silane exchange reaction, which commonly takes more
than 24 h, is an important drawback for this approach. In
this paper, we present a novel method, which introduces
ultrasonication as an energy source to dramatically
accelerate this process, resulting in high-quality waterdispersible nanoparticles around 10 nmin size. To prove
the generic character, different functional groups were
introduced on the surface including polyethylene glycol
chains, carboxylic acid, amine, and thiol groups. Their
colloidal stability in various aqueous buffer solutions as
well as human plasma and serum was investigated to
allow implementation in biomedical and sensing
applications.status: publishe
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
Aims The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p
- …